Literature DB >> 6815146

Synergistic effects of a macrolide and a cell wall-affecting antibiotic on Pseudomonas aeruginosa in vitro and in vivo. 3. Incorporation of [14C]midecamycin acetate (MOM) into P. aeruginosa pretreated with cell wall-affecting antibiotics.

T Kasai, T Tomita, S Kanegasaki, J Y Homma.   

Abstract

The occurrence in beta-lactam treated patients of unstable L-forms of Pseudomonas aeruginosa insensitive to various antibiotics and synergistic effect of combined action of cell wall-affecting antibiotics and macrolide on Pseudomonas infection led us to examine the effects of macrolide on P. aeruginosa pretreated with cell wall-affecting antibiotics. The effects of macrolide antibiotics such as midecamycin acetate (MOM) on P. aeruginosa was investigated, a rapid killing effect by MOM was noted after treatment with suboptimal doses of cell wall-affecting antibiotics such as polymyxin B, carbenicillin, dibekacin or fosfomycin. Incorporation of [14C]MOM into intact P. aeruginosa cells was not significant, but was apparent into L-form cells or cells pretreated with cell wall-affecting antibiotics. The incorporated radioactivity was found in the 70 S ribosome fraction, binding with the 50 S subunits of ribosome in both cases. These results indicate that under certain conditions a macrolide antibiotic can enter the P. aeruginosa cell.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6815146     DOI: 10.7164/antibiotics.35.1086

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  2 in total

1.  Alarmins released during local antitumor treatments play an essential role in enhancing tumor growth inhibition at treated and non-treated sites via a derivative of CCL3.

Authors:  Shiro Kanegasaki; Tomoko Tsuchiya
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 2.  Are Bacterial Persisters Dormant Cells Only?

Authors:  Jin Zou; Bo Peng; Jiuxin Qu; Jun Zheng
Journal:  Front Microbiol       Date:  2022-02-02       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.